REGN · Regeneron Pharmaceuticals, Inc. · Documents

Oct 3

Current report 8-K

Director or officer change, or executive pay

Aug 3

Current report 8-K

Financial results

Aug 3

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Revenue $2.86B ▼ 44.4% Net income $852.1M ▼ 72.5% Diluted EPS $7.47 ▼ 73.3%

Aug 3

Earnings call

Q2 2022 earnings call

Jun 15

Current report 8-K Events of Jun 10

Shareholder vote results

Jun 2

Current report 8-K Events of Jun 1

Entered into a material agreement

May 31

Tender offer SC TO-T/A

Tender offer

May 20

Tender offer SC TO-T/A

Tender offer

May 11

Tender offer SC TO-T/A

Tender offer

May 4

Current report 8-K

Financial results

May 4

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Revenue $2.97B ▲ 17.3% Net income $973.5M ▼ 12.7% Diluted EPS $8.61 ▼ 14.7%

May 4

Earnings call

Q1 2022 earnings call

May 2

Tender offer SC TO-T

Tender offer

Apr 21

Proxy statement DEF 14A Meeting Jun 10, 2022

Proxy statement

Apr 21

Proxy statement DEFA14A

Proxy statement

Apr 21

Proxy statement DEFA14A

Proxy statement

Apr 19

Tender offer SC TO-C

Tender offer

Mar 8

Current report 8-K Events of Mar 2

Entered into a material agreement, New debt or off-balance-sheet obligation

Feb 7

Annual report 10-K FY2021, ended Dec 31

Annual report for FY2021

Revenue $16.07B ▲ 89.1% Net income $8.08B ▲ 129.9% Diluted EPS $71.97 ▲ 135.8%

Feb 4

Current report 8-K

Financial results

Feb 4

Earnings call

Q4 2021 earnings call

Jan 10

Current report 8-K

Financial results, Regulation FD disclosure

Nov 4

Current report 8-K

Financial results

Nov 4

Quarterly report 10-Q FY2021 Q3, ended Sep 30

Quarterly report for FY2021 Q3

Revenue $3.45B ▲ 50.5% Net income $1.63B ▲ 93.8% Diluted EPS $14.33 ▲ 93.9%

Nov 4

Earnings call

Q3 2021 earnings call

Nov 4

Registration statement S-3ASR

Registration statement

Sep 16

Current report 8-K Events of Sep 14

Entered into a material agreement

Aug 5

Current report 8-K

Financial results

Aug 5

Quarterly report 10-Q FY2021 Q2, ended Jun 30

Quarterly report for FY2021 Q2

Revenue $5.14B ▲ 163.2% Net income $3.1B ▲ 245.4% Diluted EPS $27.97 ▲ 267.5%

Aug 5

Earnings call

Q2 2021 earnings call

Jun 16

Current report 8-K Events of Jun 11

Shareholder vote results

May 6

Current report 8-K

Financial results

May 6

Quarterly report 10-Q FY2021 Q1, ended Mar 31

Quarterly report for FY2021 Q1

Revenue $2.53B ▲ 38.3% Net income $1.12B ▲ 78.5% Diluted EPS $10.09 ▲ 85.8%

May 6

Earnings call

Q1 2021 earnings call

May 3

Proxy statement DEFA14A

Proxy statement

Apr 23

Proxy statement DEF 14A Meeting Jun 11, 2021

Proxy statement

Apr 23

Proxy statement DEFA14A

Proxy statement

Apr 23

Proxy statement DEFA14A

Proxy statement

Feb 8

Annual report 10-K FY2020, ended Dec 31

Annual report for FY2020

Revenue $8.5B ▲ 29.6% Net income $3.51B ▲ 66.0% Diluted EPS $30.52 ▲ 65.3%

Feb 5

Current report 8-K

Financial results

Jan 15

Current report 8-K Events of Jan 12

Entered into a material agreement

Jan 11

Current report 8-K

Financial results, Regulation FD disclosure

Jan 11

Earnings call

Q4 2020 earnings call

Jan 5

Current report 8-K Events of Dec 31

Director or officer change, or executive pay

Nov 5

Current report 8-K

Financial results

Nov 5

Quarterly report 10-Q FY2020 Q3, ended Sep 30

Quarterly report for FY2020 Q3

Revenue $2.29B ▲ 31.6% Net income $842.1M ▲ 25.8% Diluted EPS $7.39 ▲ 26.1%

Nov 5

Earnings call

Q3 2020 earnings call

Aug 19

Current report 8-K Events of Aug 18

Entered into a material agreement

Aug 12

Current report 8-K Events of Aug 7

Entered into a material agreement, New debt or off-balance-sheet obligation, Other events

Aug 5

Current report 8-K

Financial results